Abstract:Guizhen Zhang, 1, &ast Xuejian Li, 1, &ast Chunyun Huang, 1 Yuanyuan Jiang, 1 Jian Su, 1 Ying Hu 2 1 Guangxi Scientific Research Center of Traditional Chinese Medicine, Guangxi University of Chinese Medicine, Nanning, Guangxi, People's Republic of China; 2 Faculty of Pharmacy, Guangxi University of Chinese Medicine, Nanning, Guangxi, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jian Su, Guangxi Key Laboratory of Zhuang and Yao Ethnic Medicine, Guangxi Scientific Research Center of Traditional Chinese Medicine, Guangxi University of Chinese Medicine, 13 Wuhe Avenue, Nanning, Guangxi, 530200, People's Republic of China, Tel +86-0771-3946492, Fax +86-0771-3946492, Email Ying Hu, Department of Pharmacology, Faculty of Pharmacy, Guangxi University of Chinese Medicine, 13 Wuhe Avenue, Nanning, Guangxi, 530200, People's Republic of China, Tel +86-0771-3946492, Fax +86-0771-3946492, Email Purpose: The aim of this study was to develop a liposome gel containing levo -tetrahydropalmatine ( l -THP) and evaluate its transdermal properties. Methods: A L 16 (4 3 ) orthogonal experiment was conducted to optimize the preparation of l -THP liposomes and assess their characterization and stability in a gel. The transdermal features were analyzed through in vivo and in vitro experiments on rats and Strat-M ® membrane, respectively. The metabolism of l -THP in liver and skin S9 fractions was also studied. Results: The optimization of the orthogonal experiment revealed that the ideal mass ratio of phosphatidylcholine, cholesterol, and l -THP during preparation was 10:1:3. The resulting liposome exhibited a particle size of 68 nm, a PDI of 0.27, a drug loading of 4.33%, an encapsulation of 18.79%, and a zeta potential of − 41.27 mV. Both the l -THP and its liposome-gel formulation were found to be stable for a duration of 45 days at 4 °C and 30 °C. During the in vivo transdermal study, the maximum concentration (C max ) of l -THP from the liposome gel was 0.16 μg/mL, and the time to reach this maximum concentration (t max ) was 1.2 hours. The relative bioavailability of l -THP in the liposome gel was 233.8% compared to the emulsion. The concentration of l -THP (prepared in PBS) decreased at a rate of 0.0067 μg/mL/min in the liver S9 fraction and 0.0027 μg/mL/min in the skin S9 fraction, however, this difference was not observed when l -THP was encapsulated in liposomes. l -THP passed through the Strat-M ® membrane at a rate of 0.0032 mg/cm 2 /h and 0.002 mg/cm 2 /h for the emulsion and liposome gel, respectively. Conclusion: The optimal process for the preparation of l -THP liposomes was obtained. Compared to the emulsion, the liposomes provided greater bioavailability when used transdermally. The liposomes also provided greater stability for l -THP during storage. Graphical Keywords: liposome, transdermal property, l -tetrahydropalmatine, S9 fraction, orthogonal experiment, stability Graphical The levo -enantiomer of tetrahydropalmatine ( l -THP) is categorized as a tetrahydroprotoberberine isoquinoline alkaloid. 1 This compound is found in various plants, 2 including Corydalis yanhusuo W. T. Wang, which has been used in Chinese traditional medicine for a long time due to its ability to activate blood, reinforce vital energy, and relieve pain. 3 l -THP has been considered one of the major active compounds of Corydalis yanhusuo . 4 Its pharmacological information has been extensively reviewed in a recent publication. 2 l -THP has been shown to possess numerous pharmacological effects, such as anti-opioid-addiction, analgesic, anti-inflammatory, neuroprotective, anti-cancer, and hypotensive activity. The efficacy of l -THP is widely recognized, but its oral administration has been found to have low bioavailability. Studies conducted on rats have shown that the bioavailability of l -THP prepared in three different formulations was 10.4%, 2.5%, and 17.8%, respectively. 5 Another study on rabbits showed the bioavailability of l -THP to be 1.24%. 6 The poor bioavailability is likely due to poor intestinal absorption and first-pass metabolism. 7,8 To address this issue, a transdermal formulation may be a viable option. Transdermal drug delivery has many advantages over oral delivery, as it avoids first-pass me -Abstract Truncated-

Highly efficient pulmonary delivery of levo-tetrahydropalmatine using γ-cyclodextrin metal-organic framework as a drug delivery platform

Inhalation of Itraconazole Mitigates Bleomycin-Induced Lung Fibrosis Via Regulating SPP1 and C3 Signaling Pathway Pivotal in the Interaction Between Phagocytic Macrophages and Diseased Fibroblasts

Inhalable Cyclodextrin Metal-Organic Framework Dry Powder Enhanced Direct Pulmonary Delivery of Paclitaxel for the Treatment of Lung Cancer

Solidification of volatile D-Limonene by cyclodextrin metal-organic framework for pulmonary delivery via dry powder inhalers: In vitro and in vivo evaluation

Inhalable microparticle platform based on a novel shell-forming lipid excipient and its feasibility for respirable delivery of biologics

Inhalation of tetrandrine liposomes for the treatment of bleomycin induced idiopathic pulmonary fibrosis

Preparation and Evaluation of Inhalable Microparticles with Improved Aerodynamic Performance and Dispersibility Using L-Leucine and Hot-Melt Extrusion

Co-achievement of enhanced absorption and elongated retention of insoluble drug in lungs for inhalation therapy of pulmonary fibrosis

Customizable resveratrol spray-dried micro-composites for inhalation as a promising contender for treatment of idiopathic pulmonary fibrosis

Dandelion inspired microparticles with highly efficient drug delivery to deep lung

Paeonol loaded cyclodextrin metal-organic framework particles for treatment of acute lung injury via inhalation

Cyclodextrin MOFs modified dry powder inhalers quadruple bioavailability of luteolin to ameliorate fibrosing interstitial lung disease

Inhalable Cryptotanshinone Spray-Dried Swellable Microparticles for Pulmonary Fibrosis Therapy by Regulating TGF-β1/Smad3, STAT3 and SIRT3 Pathways

Inhalable drug-loaded silk fibroin carriers for pulmonary drug delivery

Inhaled Multilevel Size-Tunable, Charge-Reversible and Mucus-Traversing Composite Microspheres As Trojan Horse: Enhancing Lung Deposition and Tumor Penetration

Cross-Linked Thiolated Hydroxypropil-β-Cyclodextrin for Pulmonary Drug Delivery

A facile one-step jet-milling approach for the preparation of proliposomal dry powder for inhalation as effective delivery system for anti-TB therapeutics

Preparation and Evaluation of Mucus-Penetrating Inhalable Microparticles of Tiotropium Bromide Containing Sodium Glycocholate

Optimizing the design and dosing of dry powder inhaler formulations of the cationic liposome adjuvant CAF®01 for pulmonary immunization

A homogenous nanoporous pulmonary drug delivery system based on metal-organic frameworks with fine aerosolization performance and good compatibility

Preparation of the Levo-Tetrahydropalmatine Liposome Gel and Its Transdermal Study